Sezen Karakus is an Ophthalmology physician. OpenAlex indexes 40 publications with 565 citations (h-index 13); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
51 N 39th St
Philadelphia, PA 191042689
Telephone
215-662-8100Provider last certified this registry record 27 Apr 2026.
Clinical trials
- Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic
Sponsor: Johns Hopkins University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dompe US, Inc.Program year20257 payments
- Mallinckrodt Hospital Products Inc.Program year20251 payment
- Dompe US, Inc.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
42.3%Corticosteroid16.3%Prednisolone Acetate100%Part D≥56 patientsQuinolone Antimicrobial10.3%Ofloxacin100%Part D≥43 patients+ 5 more classes in this area
Anti-infectives
25.4%Macrolide18%Erythromycin100%Part D≥53 patientsTetracycline-class Drug4.6%Doxycycline Monohydrate100%Part D≥13 patients+ 1 more class in this area
Cancer & immunology
18%Calcineurin inhibitor18%Restasis49%Cyclosporine33%Cequa18%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation
Seminars in Arthritis and Rheumatism
2024 - Effect of Topical Recombinant Human Nerve Growth Factor on Corneal Epithelial Regeneration in Refractory Epithelial Keratopathy
Ocular Immunology and Inflammation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”